Device & Browser detection and switch media player for Flash & HTML5
No video player detected. Install or upgrade your video player!
';
$(document).ready(function(){
/* $('.svpplayer').attr('style','height: 449px;');
$('.ndleft_content_small2').attr('style','height: 426px;');*/
$('.ndleft_content_small2').animate({height: '+=78px'});
$('.svpplayer').animate({height: '+=79px'});
$('.svpplayer').append(img);
});
Please wait...
Please wait...
Prof. Dr. Burghardt Wittig
Chairman, Scientific & Strategy Board
Germany
MOLOGEN AG - Active immune therapies against cancer MGN1703 and MGN1601.
MOLOGEN’S lead products are MGN1703 and MGN1601. MGN1703 is a DNA-based cancer immuno-therapy with an outstanding safety profile. The drug is currently being investigated in a clinical trial phase II/III for the treatment of metastatic colorectal cancer. MGN1601 is a cancer vaccine against renal cell caner. In a clinical phase I/II trial the drug demonstrated a very good tolerability and showed first efficacy.
Legal Disclaimers
Important Notice
Information and opinions contained in this broadcast have been compiled or arrived at by the organisation making this presentation.
This broadcast is hosted, streamed and brought to you by 3B NEXUS who make no representation or warranty regarding the accuracy or reliability or completeness of any information provided and accepts no liability for any loss arising from the use hereof. Any reliance you place on such information will be at your sole risk.
Forward-Looking Statements
The information, statements and opinions contained in this broadcast do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of any offer to buy any securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.
Any statements, information and opinions contained in this broadcast, in particular those concerning investments and the possible or assumed future performance, costs, dividends, returns, production levels or rates, prices, reserves, divestments, growth or other trend projections and any estimated earnings are or may contain certain forward looking statements and as such involve risks and uncertainties.
Actual results and developments may differ materially from those expressed or implied by these statements depending on a variety of factors.
